QCG
CSTL icon

Quadrant Capital Group’s Castle Biosciences CSTL Stock Holding History

Quadrant Capital Group’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.25K Hold
336
– – ﹤0.01% 2240
2025
Q4 		$13.1K Hold
336
– – ﹤0.01% 2132
2025
Q3 		$7.65K Buy
+336
New +$6.83K ﹤0.01% 2232
2022
Q2 		– Sell
-66
Closed -$3K – 2574
2022
Q1 		$3K Buy
+66
New +$2.73K ﹤0.01% 2042

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Quadrant Capital Group's CSTL Position: Q1 2026 in Review

Quadrant Capital Group held its Castle Biosciences (CSTL) position steady in Q1 2026 at 336 shares worth $8.25K. The position accounts for ﹤0.01% of the portfolio, ranked #2240.

Quadrant Capital Group first reported a position in CSTL in Q1 2022 and has held it in 4 quarters since. The position peaked at $13.1K in Q4 2025. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • Quadrant Capital Group held 336 shares of Castle Biosciences worth $8.25K as of Q1 2026.
  • Quadrant Capital Group left its Castle Biosciences share count unchanged in Q1 2026.
  • Castle Biosciences made up ﹤0.01% of Quadrant Capital Group's portfolio in Q1 2026, its #2240 holding.
  • Quadrant Capital Group first reported a position in Castle Biosciences in Q1 2022 and has held it in 4 quarters since.
  • Quadrant Capital Group's Castle Biosciences position peaked at $13.1K in Q4 2025.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.